A Proof of Concept (POC) Clinical Trial for Post-Traumatic Stress Disorder (PTSD) With a First-In-Class Vasopressin 1a Receptor Antagonist (SRX246)

Trial Profile

A Proof of Concept (POC) Clinical Trial for Post-Traumatic Stress Disorder (PTSD) With a First-In-Class Vasopressin 1a Receptor Antagonist (SRX246)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Jun 2017

At a glance

  • Drugs SRX 246 (Primary)
  • Indications Post-traumatic stress disorders
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Azevan Pharmaceuticals
  • Most Recent Events

    • 03 Feb 2017 Status changed from not yet recruiting to recruiting.
    • 29 Sep 2016 Planned initiation date changed from 1 Jun 2016 to 1 Nov 2016.
    • 13 Apr 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top